Voluntary announcement - marketing authorization application of Aumolertinib in the EU resubmitted and validated by the EMA
Filed with HKEX · Stock code 3692 · · 1 page · English
Summary by 6ix AI
Hansoh Pharmaceutical Group Company Limited has resubmitted and received validation for its marketing authorization application for Aumolertinib in the European Union from the European Medicines Agency. The application is for Aumolertinib's use in treating advanced non-small cell lung cancer in specific patient populations. The centralized review procedure for the application has officially commenced following the validation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hansoh Pharmaceutical Group Company Limited on 6ix
Earlier from Hansoh Pharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - update on the marketing authorization status of aumolertinib in the EU
- Voluntary announcement - biologics license application of risvutatug rezetecan for injection (HS-20093) for osteosarcoma accepted by the nmpa
- Notification letter to non-registered holders and request form
- Notification letter to registered shareholders and reply form
Later from Hansoh Pharmaceutical
All Hansoh Pharmaceutical news releasesFollow Hansoh Pharmaceutical into a list and get an email when it puts out news.
Follow Hansoh Pharmaceutical